Univdatos Whatsapp

Global Atrial Fibrillation Drugs Market is expected to foresee significant growth. North America to lead the growth!

Atrial fibrillation is an irregular and often very rapid heart rhythm (arrhythmia) that can lead to blood clots in the heart. A-fib increases the risk of stroke, heart failure, and other heart-related complications. The increasing prevalence of cardiovascular diseases results in an increase in the cases of atrial fibrillation which has a positive influence on the atrial fibrillation market. For instance, one person dies every 36 seconds in the United States from cardiovascular disease. About 659,000 people in the United States die from heart disease each year—that’s 1 in every 4 deaths. Therefore, increasing demand for cardiac drugs is expected to drive the global atrial fibrillation drugs market at a CAGR of 5%, during the forecast period.

COVID-19 has a staggering effect on the global market. However, the market for atrial fibrillation drugs was not largely affected by the pandemic. This is mainly due to the COVID-19 pandemic, the government imposed strict regulations on healthcare institutions and essential treatments were allowed. Cardiac diseases come under essential care and the market for heart diseases did not affect by the pandemic.

Based on the product, the market has been categorized into anticoagulant and antiarrhythmic drugs. Among them, the anticoagulant drug segment is expected to witness lucrative growth during the forecast period. Atrial fibrillation can lead to blood clots and stroke. Consecutively, anticoagulation therapy is an important method of preventing stroke in individuals with atrial fibrillation. Hence, it raises the demand for anticoagulant drugs.

For a detailed analysis of the global atrial fibrillation drugs market browse throughhttps://univdatos.com/report/atrial-fibrillation-drugs-market/

Based on the disease type, the market has been categorized into paroxysmal atrial fibrillation, persistent atrial fibrillation, and longstanding persistent atrial fibrillation. Among them, the paroxysmal atrial fibrillation segment is expected to have significant growth in the market. Paroxysmal atrial fibrillation is an episode of AFib that occur occasionally and usually stops spontaneously. Episodes can last a few seconds, hours, or a few days before stopping and returning to normal sinus rhythm, which is the heart’s normal rhythm.

Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals are expected to witness lucrative growth during the forecast period. This is mainly due to the presence of well-qualified professionals and their specialization in the treatment of multiple diseases. Furthermore, the rising number of heart diseases and the presence of diagnostic centers and other facilities under the same roof is responsible for the segmental growth in the atrial fibrillation device market.

Request to Download Sample of this Strategic Report – https://univdatos.com/get-a-free-sample-form-php/?product_id=27935  

For a better understanding of the market adoption of the atrial fibrillation drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a significant market for atrial fibrillation devices due to the increasing number of arrhythmia cases in the region. Furthermore, the increasing geriatric population coupled with the rising number of research studies on atrial fibrillation in the region is responsible for the regional growth in the atrial fibrillation drug market. For instance, in November 2019, N.J. & The Bristol-Myers Squibb-Pfizer Alliance announced the initiation of a new randomized, controlled study, GUARD-AF. The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately impacts the rate of stroke, compared to usual standard medical care.

Some of the major players operating in the market include Pfizer Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Sanofi S.A., Bristol-Myers Squibb Company, Mitsubishi Tanabe Pharma Corporation, Johnson and Johnson, DAIICHI SANKYO COMPANY LIMITED, GlaxoSmithKline plc, and Portola Pharmaceuticals.

Global Atrial Fibrillation Drugs Market Segmentation

Market Insight, by Product

  • Anticoagulant
  • Antiarrhythmic drugs

Market Insight, by Disease Type

  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation
  • Longstanding Persistent Atrial Fibrillation

Market Insight, by End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Market Insight, by Region

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Rest of World

Top Company Profiles

  • Pfizer Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH
    • Sanofi S.A.
    • Bristol-Myers Squibb Company
    • Mitsubishi Tanabe Pharma Corporation
    • Johnson and Johnson
    • DAIICHI SANKYO COMPANY LIMITED
    • GlaxoSmithKline plc
    • Portola Pharmaceuticals

Leave A Comment

Select Language